Key Takeaways:
Alignment Healthcare Inc. faces a securities-fraud investigation after its stock plunged 16 percent on July 8 following a whistleblower lawsuit.
The lawsuit, filed by the company's former chief transformation officer, alleges Alignment deliberately misclassified $8 million to $10 million in routine operating expenses as capital expenditures within its technology sector, according to the complaint.
The reclassification artificially inflated adjusted EBITDA, the former executive alleged, letting Alignment report its "first full year of positive adjusted EBITDA as a public company." Shares fell $4.02, or 16.7 percent, to close at $20.03 per share on July 8. The Law Offices of Frank R. Cruz said July 31 it is continuing its investigation into possible violations of federal securities laws.
The probe adds legal pressure on the Medicare Advantage insurer, which trades on the Nasdaq. Kaplan Fox & Kilsheimer has separately reminded investors of potential securities claims. A finding of wrongdoing could expose Alignment to shareholder class actions, SEC enforcement and management scrutiny.
The investigation centers on how Alignment accounted for technology spending. The former executive alleged the company booked routine software maintenance and production support as capital expenditures, a treatment that defers costs and lifts operating profit in the near term. Capitalizing such outlays inflates adjusted EBITDA, a metric the company has highlighted since going public.
Alignment, which provides Medicare Advantage plans to seniors, has leaned on the adjusted EBITDA milestone to frame its path to profitability since listing on the Nasdaq. The metric strips out items including stock-based compensation and depreciation, making the treatment of capital expenditures central to how investors gauge underlying earnings. The former executive also alleged the accounting was designed to boost executive compensation tied to the EBITDA target.
The whistleblower's claims come as Alignment guides third-quarter sales of $1.300 billion to $1.320 billion, bracketing the $1.315 billion consensus estimate. The company has not commented publicly on the lawsuit. The law firm is asking investors who purchased Alignment securities to come forward and is accepting inquiries by phone and email.
The investigation puts Alignment's financial reporting under scrutiny just as it projects its first full year of positive adjusted EBITDA. Investors will watch for a restatement, SEC action or further shareholder litigation in the coming months.
This article is for informational purposes only and does not constitute investment advice.
